PLUS THERAPEUTICS, Inc. (PSTV) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen. Welcome to PLUS Therapeutics' second quarter 2024 results conference call. Before we begin, we want to advise you that over the course of the call, including any question and answer session, forward-looking statements will be made regarding events, trends, business prospects, and financial performance, which may affect PLUS Therapeutics' future operating results and financial positions. All such statements are subject to risks and uncertainties, including the risks and uncertainties described under the risk factors section included in PLUS Therapeutics' annual report on Form 10-K and quarterly reports on Form 10-Q, filed with the Securities and Exchange Commission from time to time. PLUS Therapeutics advises you to review these risk factors in considering such statements. Plus Therapeutics assumes no responsibility to update or revise any forward-looking statements to reflect events, trends, or circumstances after the date they are made. It is now my pleasure to turn the floor over to Dr. Mark Hedrick, Plus Therapeutics President and Chief Executive Officer. Sir, you may begin. Thank you, Cherie, and good afternoon, everyone. Thank you once again for taking the time to join us today as we provide an overview of of recent business highlights and discuss our second quarter 2024 financial results. Joining me on the call today is Mr. Andrew Sims, our Chief Financial Officer. I'll begin the call by reviewing our recent clinical and corporate progress in the second quarter, then turn the call over to Andrew to review our financials, and then we'll both come back on for Q&A. So let me begin with updates from the 2024 Society for Neuro-Oncology and Combined American Society for Clinical Oncology CNS Metastases Conference, which met last ...